The cumulative evidence in the past three decades situates ambulatory blood pressure monitoring (ABPM) as a central element in diagnosing and predicting the prognosis of subjects with hypertension. However, for various reasons, this diagnostic and prognostic importance has not been translated in equal measure into making decisions or guiding antihypertensive treatment. Mean 24-h, daytime, and night-time blood pressure estimates, the occurrence of divergent phenotypes between clinic measurements, and ABPM, as well as the main elements that determine blood pressure variability over 24 h, especially night-time dipping, are all elements that in addition to providing evidence for patient prognosis, can be used to guide antihypertensive treatment follow-up enabling greater precision in defining the effect of the drugs. In recent years, specific indices have been developed using 24-h monitoring, evaluate the duration of treatment action, the homogeneity of the effect over the monitoring period, and its possible effects on variability. In future controlled clinical trials on antihypertensive therapies it is necessary to evaluate the effects of those treatments on hard endpoints based on therapy guided by ABPM.
individual's organ damage and cardiovascular prognosis [1] [2] [3] [4] . Moreover, regarding diagnostic aspects, ABPM has enabled two new phenotypes to be defined, white-coat hypertension (HTN) and masked HTN, both of great clinical interest [5, 6] . Applying ABPM to therapeutic assessment has had less of an impact, both on the part of the investigators as well as on the part of the investment made by the sponsors of antihypertensive drugs and devices. A large part of this is motivated by the fact that the regulatory authorities continue to consider clinic BP measurement as the central element for approving antihypertensive drugs and devices. Nevertheless, the BP measurement indicators obtained using ABPM, the patient phenotypes during hypertensive treatment, dipping patterns, and BP variability over 24 h of monitoring, are of equally high interest when analyzing the effects of antihypertensive therapies [7] . Furthermore, using ABPM 
MEAN 24-H, DAYTIME, AND NIGHT-TIME BP ESTIMATORS
The mean 24-h, daytime, and night-time indicators have classically been the most used for both the relationship between ambulatory BP and cardiovascular prognosis, as well as for assessing the antihypertensive effect of drugs. Daytime BP, or BP during the period of activity, was one of the first parameters studied, since it is considered the closest to in-office BP. The current guidelines for diagnosing and treating HTN from the National Institute for Health and Care Excellence (NICE) of the British Government advises practicing ABPM during the day to confirm the HTN diagnosis when the clinic figures are high [8] . Daytime BP has also been the first used to assess the ''white-coat'' effect. In the first analyses of the Spanish ABPM Registry, up to 30% of patients without treatment [9, 10] and nearly 35% of those treated with clinic BP figures greater than or equal to 140/90 mmHg [11] presented normal daytime BP figures (below 135/85 mmHg).
One study has used daytime BP to guide antihypertensive treatment adjustment and monitoring in comparison with clinic BP [12] . Thus, patients with a clinic diastolic BP greater than or equal to 95 mmHg were randomized to using daytime BP or clinic BP to guide treatment adjustments. Upon ending the study, the daytime BP-guided monitoring was associated with a lower use of antihypertensive drugs; with no differences observed in the organ damage measured using the degree of left ventricular hypertrophy.
The mean BP of all measurements made over 24 h of monitoring is considered to be the one that provides better information. A larger number of measurements are included in its calculation. As such, it is less affected by sporadic situations that may arise during the day or night or by sporadic errors. It takes into account daytime activity, work, and the changes in pressure caused by those activities, Thus, in one of them that included 44 studies with more than 5000 patients, the mean decreases in clinic BP were 19/10 mmHg, while those corresponding to the 24-h figures were 13/8 mmHg. The percentage of 24-h BP reductions compared to clinic BP was 65% and 81%, respectively, for systolic and diastolic BP [13] .
Another conclusion reached in that meta- the one that is best correlated with the prognosis [1] [2] [3] [4] . Its main advantage is that it can be considered the baseline BP (the one that is specified for tissue perfusion in a state of rest). In addition, the fact that it is generally measured at rest gives it higher reproducibility and less variability, which makes it easier to correlate it with organ damage and prognosis. The data from the Spanish ABPM Registry [4] , as well as the various prospective cohort databases [15] , indicate that of all the BP indicators (clinic, daytime, night-time, and 24-h) it is the one that is best independently correlated with the prognosis (Fig. 1) . The main disadvantages are that it requires an exact definition of the rest period, it may be affected by the presence of a daytime rest (nap) [16] , and it is equally affected by the quality of sleep [17] , especially in patients who repeatedly wake up during the night or who have sleep apnea. Similarly, its association with organ damage has been described as similar to that of normotensive individuals in some studies, or with a higher prevalence of cardiac or renal damage in others. In many cases, it is hard to reach a conclusion since, even with the whitecoat HTN diagnosis, these individuals have higher ABPM figures than normotensive individuals and, in addition, a very high percentage go on to develop sustained HTN in its progression [22] .
PATIENT PHENOTYPES
The prevalence of these divergent phenotypes depends in large part on the parameter used to define them and the study population. and early detection of the appearance of sustained HTN seems to be the best option [27] .
DIPPING PATTERNS
The decrease in BP caused by rest and sleep, usually at night, has a favorable impact on reducing the pressure burden related to the organ damage. Almost 40 years ago, it was described that some patients in whom this night-time dip was less pronounced (the threshold has been established at 10% versus the daytime values) had a worse risk profile and a higher probability of developing cardiovascular events and death [28] . In general, four dipping patterns have been described based on this night-time decrease. The most common pattern in the healthy population is known as the ''dipper'' pattern and it represents between a 10% and 20% decrease from daytime values. The extreme ''dipper'' pattern exceeds this 20% and, even though it has been described as associated with a risk of cerebrovascular accident in the Asian population, a clearly deleterious effect has not been demonstrated on the prognosis in Westerners. Conversely, a decrease below 10%, known as a ''non-dipper'' pattern (recently the term ''reduced dipper'' has been proposed), or an increase in BP during rest, known as a ''riser'' pattern, have both been associated with a worse prognosis and related with organ damage [28, 29] .
The data from the Spanish ABPM Registry have allowed us to determine that the prevalence of these ''deleterious'' patterns is very high, approaching 50% of untreated patients and exceeding this figure in those on treatment (Fig. 4) . Old age, the female sex, obesity, diabetes, and a history of previous cardiovascular disease are associated with an inadequate decrease in both treated and untreated patients. In treated patients, increasing the number of drugs also results in a higher probability of presenting a non-dipper or riser pattern [30, 31] .
The 
MORNING HTN AND MORNING SURGE
After the sleep-induced night-time BP dip, the morning surge that accompanies waking is a physiological phenomenon. However, some studies have observed that an exaggerated morning BP surge is associated with a higher rate of cardiovascular events [33] . The hormone changes that affect cortisol and catecholamines, 
BP VARIABILITY
BP is a dynamic parameter that fluctuates based on several circumstances, some intrinsic and other extrinsic [36] . Long-term BP variability may be determined through successive visits. This variability has a prognostic impact, especially in predicting cerebrovascular accidents [37] . ABPM enables short-term fluctuations to be assessed. Some of these, caused by the activity/rest rhythm, have already been mentioned and are part of the night-time dip patterns. However, pressure fluctuations within one of these periods (daytime and especially at night) also have a prognostic impact. They can be evaluated by calculating the standard deviation in one of the periods separately and by using indices that take into account these deviations, and project the calculation over the entire 24-h period [36] .
In recent years, there has been a growing interest in assessing the impact of antihypertensive treatment on this short-term variability determined by ABPM. Initial studies have used modifications in the posology of the drugs (administering part or all of the treatment at night) and assessed their impact on the dipping pattern.
Thus, it has been demonstrated that this night-time administration promotes a larger night-time dip and, as such, a proportion of non-dipper or riser patients becomes dippers. In one of these studies, this phenomenon was associated with a better cardiovascular prognosis [38] .
THERAPEUTIC INDICES OBTAINED USING ABPM
In addition to all the above-described parameters used to assess the effect of antihypertensive therapy, some mathematical indices have been developed that combined potency, duration of action, and homogeneity of effect. This allows for a better assessment of the effects of antihypertensive treatment.
The first of these indices is the trough-topeak (T/P) ratio. Interest in this ratio appeared nearly two decades ago and consists of calculating the ratio between the decrease in BP obtained in the hours just before the end of the therapeutic window (with drugs administered once a day between 22 and 24 h after administration) and the maximum effect calculated after several hours (between 4 and 6 h after administration). In theory, the closer it is to unity, the greater the homogeneity of effect, suggesting that the residual effect of the drug is close to its maximum effect. However, the T/P ratio has two significant problems. The first is a result of poor reproducibility, caused by the need to extract short periods of monitoring from a 24-h ABPM that may be influenced by external factors. Thus, the peak period or maximum effect may coincide with a postprandial rest (nap), which will magnify it, or with a period of higher physical or mental activity, which will minimize it. For its part, calculating the trough effect may coincide with the last hours of sleep or with waking, both circumstances that may change it. In addition, the T/P ratio does not take into account the magnitude of the antihypertensive effect, so that minimal decreases in BP in the peak will be associated with high T/P indices (placebos usually have a T/P index around 1) [39] .
The second index that measures homogeneity of effect is called the smoothness index (SI) [40] . It is calculated based on the hourly reductions in BP, corrected by the standard deviation of those reductions. Thus, the greater the magnitude of the hourly reduction and the smaller the differences between those reductions (less variability), the higher the resulting number will be. The higher the SI value is, the higher the drug potency and the greater the homogeneity of effect. Some studies have described an ability of the SI to predict changes in organ-damage parameters In a broad study stemming from patients in the Spanish ABPM Registry, one-third of 8295 patients who could be categorized as resistant hypertensive had normal 24-h BP figures, where resistance was due to a white-coat effect.
Compared with truly resistant hypertensive patients, the organ damage in these patients was less and the cardiovascular prognosis better [24] . 
